Table I.
Associations between genetic variants in cell cycle pathway and survival in the patients with stages III–IV NSCLC stratified by therapeutic regimens
| Gene | SNP/genotype | Alive/dead, n | HR (95% CI)a | P |
| Chemotherapy alone | ||||
| CCNB2 | rs1486878 | |||
| CC | 26/92 | 1 (Reference) | ||
| CG | 20/93 | 1.69 (1.23–2.33) | 0.0011 | |
| GG | 5/24 | 1.69 (1.01–2.82) | 0.0457 | |
| Dominant | 1.69 (1.25–2.30) | 0.0007 | ||
| Recessive | 1.27 (0.78–2.06) | 0.3287 | ||
| Additive | 1.41 (1.13–1.76) | 0.0023 | ||
| rs10851643 | 1.60 (1.19–2.14) | 0.0017 | ||
| AA | 28/99 | 1 (Reference) | ||
| AC | 17/92 | 1.66 (1.22–2.25) | 0.0011 | |
| CC | 6/18 | 1.34 (0.79–2.28) | 0.2812 | |
| Dominant | 1.60 (1.19–2.14) | 0.0017 | ||
| Recessive | 1.06 (0.64–1.76) | 0.8196 | ||
| Additive | 1.31 (1.06–1.62) | 0.0119 | ||
| CCND1 | rs1683847 | |||
| GG | 23/57 | 1 (Reference) | ||
| GT | 23/99 | 1.38 (0.99–1.94) | 0.0598 | |
| TT | 5/53 | 1.81 (1.19–2.75) | 0.0056 | |
| Dominant | 1.48 (1.07–2.04) | 0.0168 | ||
| Recessive | 1.47 (1.03–2.10) | 0.0331 | ||
| Additive | 1.35 (1.09–1.66) | 0.0049 | ||
| CCND2 | rs12230555 | |||
| CC | 26177 | 1 (Reference) | ||
| CT | 33/92 | 0.76 (0.55–1.06) | 0.1069 | |
| TT | 9/46 | 1.60 (1.01–2.53) | 0.0473 | |
| Dominant | 0.86 (0.64–1.18) | 0.3728 | ||
| Recessive | 1.90 (1.26–2.87) | 0.0023 | ||
| Additive | 1.12 (0.88–1.42) | 0.3606 | ||
| CDC2 | rs2127355 | |||
| AA | 13/67 | 1 (Reference) | ||
| AG | 26/104 | 0.69 (0.50–0.96) | 0.0273 | |
| GG | 12/38 | 0.51 (0.33–0.79) | 0.0022 | |
| Dominant | 0.64 (0.47–0.87) | 0.0045 | ||
| Recessive | 0.65 (0.45–0.95) | 0.0267 | ||
| Additive | 0.71 (0.57–0.88) | 0.0017 | ||
| CHEK2 | rs743185 | |||
| CC | 38/142 | 1 (Reference) | ||
| CT | 13/59 | N/A | N/A | |
| TT | 0/8 | N/A | N/A | |
| Dominant | 1.58 (1.15–2.17) | 0.0050 | ||
| Recessive | N/A | N/A | ||
| Additive | N/A | N/A | ||
| E2F3 | rs942042 | |||
| AA | 45/147 | 1 (Reference) | ||
| AG | 6/58 | N/A | N/A | |
| GG | 0/4 | N/A | N/A | |
| Dominant | 1.63 (1.18–2.25) | 0.0031 | ||
| Recessive | N/A | N/A | ||
| Additive | N/A | N/A | ||
| RB1 | rs9568029 | |||
| CC | 30/82 | 1 (Reference) | ||
| CT | 13/84 | 1.78 (1.28–2.48) | 0.0007 | |
| TT | 8/43 | 1.36 (0.89–2.09) | 0.1540 | |
| Dominant | 1.64 (1.20–2.23) | 0.0018 | ||
| Recessive | 1.02 (0.69–1.50) | 0.9385 | ||
| Additive | 1.23 (1.02–1.50) | 0.0343 | ||
| rs7329938 | DOM | 1.68 (1.17–2.41) | 0.0046 | |
| CC | 43/165 | 1 (Reference) | ||
| CT | 7/42 | N/A | N/A | |
| TT | 1/2 | N/A | N/A | |
| Dominant | 1.68 (1.17–2.41) | 0.0046 | ||
| Recessive | N/A | N/A | ||
| Additive | N/A | N/A | ||
| Chemoradiation | ||||
| TP73 | rs3765701 | |||
| AA | 31/75 | 1 (Reference) | ||
| AT | 44/114 | 1.07 (0.77–1.49) | 0.6971 | |
| TT | 16/57 | 1.94 (1.32–2.86) | 0.0007 | |
| Dominant | 1.27 (0.93–1.73) | 0.1329 | ||
| Recessive | 1.87 (1.35–2.59) | 1.8 × 10−4 | ||
| Additive | 1.38 (1.12–1.69) | 0.0020 | ||
The significant results after multiple comparisons were shown in boldface (FDR-adjusted P-value, q < 0.1). N/A, the number of the rare homozygotes was <5%; therefore, only dominant model was applied.
a
Adjusted for age, gender, ethnicity, smoking status, performance status and clinical stage.